- Home
- AQST vs CRMD Comparison
AQST vs CRMD Comparison
Compare AQST & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AQST | CRMD |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.4M | 590.7M |
| IPO Year | 2007 | 2009 |
Fundamental Metrics
Financial Performance| Metric | AQST | CRMD |
|---|---|---|
| Price | $4.67 | $7.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $9.00 | ★ $14.83 |
| AVG Volume (30 Days) | ★ 2.7M | 883.2K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.72 |
| Revenue | $67,430,000.00 | ★ $311,709,000.00 |
| Revenue This Year | $10.08 | $0.30 |
| Revenue Next Year | $49.60 | N/A |
| P/E Ratio | ★ N/A | $10.88 |
| Revenue Growth | 0.77 | ★ 617.03 |
| 52 Week Low | $2.94 | $6.13 |
| 52 Week High | $7.55 | $13.02 |
Technical Indicators
Market Signals| Indicator | AQST | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.60 | 44.37 |
| Support Level | $4.03 | $7.09 |
| Resistance Level | $5.10 | $9.01 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 23.73 | 12.92 |
Price Performance
Historical ComparisonAbout AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.